Claudia Lee was the director of discovery at the University of Pennsylvania’s Gene Therapy Program and worked with industry sponsors to take CAR-T, in vivo gene editing, AAV and mRNA therapy to the clinic and tech transfer the early stage research assays into GMP.  She addresses ATMP early stage development using the same principles from her training in liposomal drug delivery, antibody discovery and process development. She worked with West Pharmaceutical Services during the COVID-19 pandemic to secure the stability of the COVID-19 vaccines. Post the pandemic, she was the director on the Moderna/Carisma in vivo CAR collaboration utilizing mRNA-LNP to repgrogram macrophages against hepatocellular carcinoma. She is now with Velvet Therapeutics in Houston Texas, working to enhance the durability and redosability of in vivo CAR using its DNA platform.